Michael P. Bailey - Dec 20, 2022 Form 4 Insider Report for AVEO PHARMACEUTICALS, INC. (AVEO)

Role
President & CEO, Director
Signature
/s/ Danielle V. Holland, attorney in fact
Stock symbol
AVEO
Transactions as of
Dec 20, 2022
Transactions value $
$1,248,144
Form type
4
Date filed
12/22/2022, 03:46 PM
Previous filing
Feb 17, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVEO Common Stock Options Exercise $164K +26.5K +46.97% $6.20 82.9K Dec 20, 2022 Direct F1
transaction AVEO Common Stock Options Exercise $480K +85.7K +95.33% $5.60 176K Dec 20, 2022 Direct
transaction AVEO Common Stock Options Exercise $604K +165K +93.67% $3.67 340K Dec 20, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVEO Stock Option (right to buy) Options Exercise $0 -26.5K -22.08% $0.00 93.5K Dec 20, 2022 Common Stock 26.5K $6.20 Direct F2
transaction AVEO Stock Option (right to buy) Options Exercise $0 -85.7K -70.83% $0.00 35.3K Dec 20, 2022 Common Stock 85.7K $5.60 Direct F3
transaction AVEO Stock Option (right to buy) Options Exercise $0 -165K -20.83% $0.00 625K Dec 20, 2022 Common Stock 165K $3.67 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,110 shares purchased by the Reporting Person under the Company's 2010 Employee Stock Purchase Plan, as amended.
F2 The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company.
F3 The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company.
F4 The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company.